Kalohexis is a clinical-stage biotechnology company shaping the next era of obesity and metabolic disease care by harnessing the melanocortin (MC) system, the body’s natural regulator of metabolic homeostasis, to help people live healthier lives. Our first- and best-in-class therapeutic peptides are designed to safely and effectively drug central melanocortin 3 and 4 receptors (MC3R/MC4R) to treat many metabolic disorders. Our lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist to induce higher quality, more durable weight loss, and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in patients with advanced cancers.

Beyond obesity and cachexia, our pipeline includes first-in-class MC4R-selective and MC3R-selective agonists with the potential to address multiple metabolic indications with significant unmet needs, including type 2 diabetes, metabolic dysfunction-associated steatohepatitis, opioid use disorder, sarcopenia, polycystic ovary syndrome, muscle retention adjuvant, and menopausal weight maintenance.

For more information, visit www.kalohexis.com.

Kalohexis

This department oversees medical and discovery strategies to drive innovation and ensure compliance within healthcare initiatives.

Kalohexis

Org chart

Teams

Medical and Discovery Leadership

Offices